British healthcare body recommends Thrombogenics drug

BRUSSELS (Reuters) – Belgian biotech group Thrombogenics said on Wednesday that it received a positive initial recommendation from British healthcare body NICE that its eye drug Jetrea qualify for reimbursement to patients. The company said a final decision is expected in the third quarter of this year. (Reporting by Robert-Jan Bartunek; Editing by Edwina Gibbs)